Table 3 Risks of active tuberculosis infection during anti-TNF therapy, derived from a Cox proportional hazards model
|  | TB + group (n = 21) | TB- group (n = 1413) | Hazard ratio (95% CI) | p value | |
|---|---|---|---|---|---|
Age at anti-TNF (years) | 39.57 | 31.22 | 1.041 (1.014–1.069) | 0.002 | |
Age of IBD diagnosis (years) | 32.81 | 25.70 | 1.039 (1.012–1.067) | 0.005 | |
Female | 9 (42.9) | 485 (34.3) | 1.286 (0.541–3.055) | 0.570 | |
IBD type |  |  | 0.660 (0.254–1.714) | 0.393 | |
 UC | 6 (28.6) | 323 (23.1) |  |  | |
 CD | 15 (71.4) | 1087 (76.9) |  |  | |
History of smoking | 10 (47.6) | 433 (30.6) | 2.094 (0.889–4.932) | 0.091 | |
Previous TB history | 1 (4.7) | 48 (3.4) | 1.297 (0.174–9.665) | 0.800 | |
Screening for LTBI |  |  | 1.170 (0.417–3.284) | 0.765 | |
 IGRA + TST | 15 (71.4) | 951 (67.3) |  |  | |
 IGRA | 5 (23.8) | 361 (25.5) |  |  | |
LTBI | 3 (14.3) | 195 (13.8) | 0.896 (0.262–3.066) | 0.862 | |